India’s Glenmark Pharmaceuticals has agreed to sell development and commercialisation rights of their promising new painkiller to France’s Sanofi-Aventis SA.
Glenmark will receive an upfront payment of $20m for the molecule known as GRC 15300 and will also be eligible for milestone payments that could total $325m.
GRC 15300 is currently in the first phase of human trials as a treatment for various pain conditions, including diabetic neuropathic pain and osteoarthritic pain.
Glenmark will also be eligible to receive royalties in double-digit percentages of potential sales after the product launch, which is expected in the next five to six years.
Sanofi-Aventis will have exclusive marketing rights for North America, the European Union and Japan, subject to Glenmark’s right to co-promote the products in the US and five Eastern European countries.
Sanofi-Aventis will also have co-marketing rights in ten other countries, including Brazil, Russia and China, whereas Glenmark will retain exclusive rights in India and other countries in the rest of the world.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData